Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it will participate in the American Academy of Dermatology (AAD) Annual Meeting to take place March 1 - 5, 2019 at the Walter E. Washington Convention Center, in Washington D.C.
Clinical data on the Company's late stage clinical development candidates, FMX101 for moderate to severe acne, and FMX103 for papulopustular rosacea, are expected to be covered in oral presentations by leading clinical dermatologists during the meeting. The Company will also host a medical affairs booth, with medical affairs staff on-site to answer qu estions on its clinical data as well as on its proprietary foam technology.
The American Academy of Dermatology is one of the largest, non-partisan professional organizations of dermatologists in the world. Each year, AAD convenes an annual meeting to discuss the latest advances and trending topics in dermatology in more than 300 educational sessions across various tracks. Last year's AAD meeting drew more than 18,750 attendees.
"This is a great opportunity for the medical community to hear some of the most recent clinical study data on our late stage candidates for acne and rosacea," said David Domzalski, C EO of Foamix. "We submitted our New Drug Application (NDA) for FMX101 to the US FDA late last year, with an anticipated PDUFA date in Q4 2019, and are planning to submit another NDA for FMX103 in rosacea in mid-2019. The combined total body of clinical data supporting these candidates, including positive results from Phase 3 trials, suggests that they have the potential to address significant unmet needs in their respective dermatology indications. Pending regulatory approvals by FDA, Foamix could be in a position to commercialize FMX101 in early 2020 followed by FMX103 in the second half of 2020."
Medical Affairs Booth:
Booth # 4301
Open: March 1 - 2 from 10am to 5pm; March 3 from 10am to 3pm
Relevant Presentations and Details:
Session: New Emerging Therapies (S003)
Date and Tim e: Friday March, 1 9:48 a.m., Eastern Time
Location: Ballroom C
Presenter: Dr. Diane Bersen
Presentation: New and Emerging Therapies for Acne and Rosacea
Session: Acne Boot Camp (F005)
Date and Time: Friday March 1, 10:30 a.m., Eastern Time
Location: Ballroom B
Presenter: Dr. Leon Kircik
Presentation: New and Emerging Treatments for Acne
Session: Acne and Rosacea (S043)
Location: Room 207A
Date and Time: Sunday March 3, 1:23 p.m., Eastern Time
Presentation: Acne: What's new and What's on the Horizon?
Date and Time: Sunday March 3, 2:30 p.m., Eastern Time
Presenter Dr. Hilary Baldwin
Presentation Rosacea: What's New?
AI
